Catalyst
Slingshot members are tracking this event:
Sarepta's (SRPT) Eteplirsen Approved by FDA for Duchenne Muscular Dystrophy After Long Approval Process
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 19, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Eteplirsen, Duchenne Muscular Dystrophy, Fda Approval
